Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Moderna Inc. | V940-001 (mRNA-4157) with KEYTRUDA (pembrolizumab) - (INTerpath-002) | Personalized cancer vaccine, high-risk melanoma, lung cancer | Phase 3 | Data Released | Intravenous | Oncology |
| Moderna Inc. | mRNA-1608 | Herpes simplex virus (HSV) | Phase 3 | Trial Discontinued | Intramuscular | Antiviral |
| Moderna Inc. | mRNA-1468 | Shingles (herpes zoster) | Phase 3 | Trial Discontinued | Intramuscular | Antiviral |
| Moderna Inc. | mRNA-3705 | Methylmalonic Acidemia | Phase 3 | Trial Planned | Intravenous | Genetic Disorder |
| Moderna Inc. | mRNA-1647 - (CMVictory) | CMV vaccine (Cytomegalovirus Infection) | Phase 3 | Trial Discontinued | Intramuscular | Immunology |
| Moderna Inc. | V940 (mRNA-4157) + KEYTRUDA (pembrolizumab) - (INTerpath-009) | Non-small cell lung cancer (NSCLC) | Phase 3 | Enrollment Initiation | Intravenous | Oncology |
| Moderna Inc. | mRNA-1345 | RSV in adults over 50 years of age to evaluate co-administration and revaccination | Phase 3 | Trial Completed | Intramuscular | Respiratory |
| Moderna Inc. | mRNA-1273.211 | Bivalent booster vaccine candidate | Phase 2/3 | Data Released | Intramuscular | COVID-19 |
